Sanofi (SNY)

42.38
0.47 1.10
NYSE : Health Technology
Prev Close 41.91
Day Low/High 42.03 / 42.59
52 Wk Low/High 37.43 / 50.65
Avg Volume 2.14M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 104.59B
EPS 1.70
P/E Ratio 22.53
Div & Yield 1.20 (2.98%)
Will the Government Shutdown Kill the Mind-Blowing Bull Market?

Will the Government Shutdown Kill the Mind-Blowing Bull Market?

The stock market's impressive start to the year is at risk as the government shutdown enters day three. Meanwhile, a series of healthcare deals captivates Wall Street's attention.

Government Shutdown and Everything Else You Need to Know Monday Morning

Government Shutdown and Everything Else You Need to Know Monday Morning

So what does a government shutdown mean for today's trading? Here's what you need to know before Monday's opening bell.

Shutdown Enters Day 3, Sanofi Buys Bioverativ - 5 Things You Must Know

Shutdown Enters Day 3, Sanofi Buys Bioverativ - 5 Things You Must Know

U.S. stock futures suggest Wall Street will open lower on Monday, as investors watch for the impact of a federal government shutdown that has extended into its third day.

Sanofi Strikes $11.6 Billion Deal for Bioverativ

Sanofi Strikes $11.6 Billion Deal for Bioverativ

France's Sanofi could end its long search for a biotech deal after striking an $11.6 billion offer for Massachusetts-based Bioverativ, a maker of hemophilia treatments.

FCC's Dismantling of Net Neutrality Could Spur New Wave of Telco M&A

FCC's Dismantling of Net Neutrality Could Spur New Wave of Telco M&A

Helped by a relaxed regulatory environment, telco giants could pursue M&A to build and prioritize their own content libraries.

Sanofi Explores Combination Treatments For Multiple Myeloma In New Late-stage Trials

Sanofi Explores Combination Treatments For Multiple Myeloma In New Late-stage Trials

Sanofi has launched two new late-stage clinical studies to determine if an investigational biologic called isatuximab, when used in combination with other commonly used cancer treatments, might be an effective treatment...

Winners and Losers in a Temporary French Tax Revolution

Winners and Losers in a Temporary French Tax Revolution

Some French companies will get a temporary windfall, but others will need to pay more tax.

These 16 Stocks Look Ready to Reverse

These 16 Stocks Look Ready to Reverse

Tesla and General Motors are among this week's names showing reversal patterns.

Sanofi Falls After Third-Quarter Sales Narrowly Miss Forecasts

Sanofi Falls After Third-Quarter Sales Narrowly Miss Forecasts

The French drugmaker's under pressure diabetes treatments slid less than expected but sales of its growing multiple sclerosis products underwhelmed.

Sanofi, Shell and Credit Suisse -- Earnings Round-Up

Sanofi, Shell and Credit Suisse -- Earnings Round-Up

Investors keep an eye on another busy slate of earnings.

Washington Uncertainty and a Healthcare Selloff Send Stocks Lower

Washington Uncertainty and a Healthcare Selloff Send Stocks Lower

Uncertainty in Washington, D.C., a healthcare sector in selloff mode and a big deals day on Wall Street sent U.S. equities lower to begin the week.

Stocks Burrow Further Into the Red on Logistics of Tax Cut Plan

Stocks Burrow Further Into the Red on Logistics of Tax Cut Plan

Stocks dig further into the red on Monday, Oct. 30, as investors weigh how a proposed phase-in corporate tax rate cut might impact U.S. companies.

Merck Weighs on Dow but Apple and Tech Rally Give Lift to Nasdaq

Merck Weighs on Dow but Apple and Tech Rally Give Lift to Nasdaq

Stocks are mixed on Monday as Mueller's Russia investigation takes its first concrete steps.

The Hartford, Aetna Ink Tie-Up; All Eyes on Peanut Allergies -- ICYMI

The Hartford, Aetna Ink Tie-Up; All Eyes on Peanut Allergies -- ICYMI

Here's what you need to know now for Monday, Oct. 23.

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.

Flexion's Latest FDA Approval Reignites Takeover Chatter

Flexion's Latest FDA Approval Reignites Takeover Chatter

The Burlington, Mass.-based pharmaceutical firm on Oct. 6 secured approval from the Food and Drug Administration for its osteoarthritis knee pain treatment Zilretta, a non-opioid medicine.

Pfizer Consumer Unit Worth as Much as $14 Billion

Pfizer Consumer Unit Worth as Much as $14 Billion

A deal would give the company capital to do more deals but the decision also keeps the company's recently scratched plans to split into two separate companies alive. The division itself had about $3.4 billion in 2016 sales and houses brands such as Advil, Chaptstick, Centrum and Preparation H, among others.

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

Robert Herjavec Predicts New Legislation in Response to the Equifax Hack

Robert Herjavec Predicts New Legislation in Response to the Equifax Hack

Shark Tank's Robert Herjavec on why the Equifax hack is different from others cyber attacks.

Alnylam And Sanofi Report Positive Topline Results From APOLLO Phase 3 Study Of Patisiran In Hereditary ATTR (hATTR) Amyloidosis Patients With Polyneuropathy

Alnylam And Sanofi Report Positive Topline Results From APOLLO Phase 3 Study Of Patisiran In Hereditary ATTR (hATTR) Amyloidosis Patients With Polyneuropathy

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the APOLLO Phase 3 study of...

Biotech Mailbag: Buy Dip in T2 Biosystems?

Biotech Mailbag: Buy Dip in T2 Biosystems?

Plus, what's going on with Lexicon Pharmaceuticals?

FDA Official Calls for Ending Codeine Use in Kids Cough Products

FDA Official Calls for Ending Codeine Use in Kids Cough Products

An FDA advisory panel recommends that warnings on cough syrups be extended from young children to everyone under 18.

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

A small portion of the population is prone to "ultra-metabolize" codeine at rates far in excess of the general population.

Sanofi Has Good Potential Upside

Sanofi Has Good Potential Upside

I would buy strength above $50 and $51 in Sanofi.

European Pharma Companies Slip on MS Pricing Probe

European Pharma Companies Slip on MS Pricing Probe

House Democrats start probe into MS drug prices

Mylan Finalizes $465 Million EpiPen Settlement With DoJ

Mylan Finalizes $465 Million EpiPen Settlement With DoJ

The dispute became the center of a drug price firestorm.

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.

Sanofi Is Selling a Ton of Vaccines So It Decided to Hike Its Profit Outlook

Sanofi Is Selling a Ton of Vaccines So It Decided to Hike Its Profit Outlook

Sanofi is starting to offset diabetes franchise losses

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

TheStreet Quant Rating: B (Buy)